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Introduction
The hemostatic system, composed by soluble coagulation proteins, platelets, endothelium, natural anticoagulants, fibrinolytic system and their inhibitors, is driven by several regulatory mechanisms responsible for initiation, propagation, stabilization and clot lysis [1] . Countless diseases in intensive care unit (ICU) are associated with systemic inflammatory response syndrome (SIRS) and endothelial damage, which compromise the delicate and complex balance between anticoagulant and procoagulant systems [2] . As a result, clinical manifestations of varying degrees of hemorrhage or thrombosis may occur, impacting on patients outcomes [3] .
Conventional coagulation tests (CCT) such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), traditionally used to evaluate coagulation disorders, have limited accuracy to characterize the hemostatic profile and predict bleeding risk in critical ill patients [3, 4] . Moreover, CCT are unable to access clot strength and clot stability since such tests are read at the beginning of the fibrin polymerization process when only approximately 5% of thrombin generation occurred [5] . Furthermore, CCT are performed in plasma samples. Therefore, information concerning platelet-function, fibrinolysis and hypercoagulability is not provided [5, 6] . Finally, CCT results may take up to 60 minutes to be available, precluding a fast and dynamic coagulation evaluation at bedside [3, 6] .
Rotational thromboelastometry (ROTEM) allows a dynamic evaluation of clot viscoelastic properties through graphic representation of clot formation, thrombin generation, fibrin polymerization and clot lysis [7] . ROTEM is performed in a whole blood sample. Therefore, its analysis takes into account the complex interactions between different blood cells and their biochemical characteristics, accessing blood hemostatic profile in real time at bedside [7] .
Blood transfusion has been associated with increased morbidity, mortality, length of ICU and hospital stay and costs [8] [9] [10] . The implementation of thromboelastometry-driven transfusion algorithms has led to a significant reduction in blood components transfusion in different populations of perioperative in critically ill patients [11] [12] [13] . Therefore, thromboelastometry has been considered safer and more cost-effective than CCT for diagnosis and management of complex cases of coagulation disorders involving critically ill patients [14] .
Objectives
The main purpose of this study was to describe the coagulation profile of critically ill bleeding patients admitted to the ICU based on ROTEM and CCT. Additionally, we aimed to determine the frequency of allogeneic blood transfusion and hemostatic drugs administration in this population of critically ill patients.
Methods

Study design
This was a retrospective, single-center, observational study performed in a medical-surgical ICU in a tertiary care hospital. This study was approved by the Research Ethics Committee of Hospital Israelita Albert Einstein (CAAE: 37519814.0.0000.0071) and informed consent was waived.
Participants
Adult patients (!18 years) admitted to the ICU, in whom ROTEM analyses were performed for bleeding manageent between September 1, 2012 and September 30, 2014 were included in this study.
Collected variables
Demographic data, comorbidities, admission type (medical or surgical), diagnosis at ICU admission, Simplified Acute Physiologic Score (SAPS) 3 [15] 
Coagulation analysis
Rotational thromboelastometry. Rotational thromboelastometry (ROTEM1, TEM International GmbH, Munich, Germany) analyses were performed with EXTEM (extrinsic coagulation pathway assessment), INTEM (intrinsic coagulation pathway assessment) and FIBTEM (extrinsic coagulation pathway assessment with additional platelet inhibition using Cytochalasin D) tests according to the manufacturer's instructions [16] . The following parameters were recorded during ROTEM analysis: clotting time [CT; seconds (sec)], which represents the beginning of the test until clot firmness of 2 mm; clot formation time (CFT; sec), which represents time between detection of a clot firmness of 2 and 20 mm; and maximum clot firmness (MCF; mm), which represents the greatest amplitude of thromboelastometric trace and reflects clot "strength" [3] .
ROTEM tests were performed by laboratory technicians. Blood samples of approximately 3 ml were collected by venipuncture into a tube with citrate (3.2%; Sarsted1, Wedel, Germany). Blood samples were processed within a maximum period of two hours for ROTEM analysis. The analyses were performed by pipetting 340 μl of citrated whole blood and 20 μl of 0.2 M calcium chloride with specific activators into a cup [16] . There was no change in methodology for test performance nor test controls (Rotrol N and Rotrol P) throughout the study period.
Normal coagulation profile on the ROTEM was defined according to reference values for CT, CFT [17] .
Conventional coagulation tests. Plasma fibrinogen concentration [Clauss method (Fibrinogen STAGO, Diagnostica Stago, Asnieres-sur-Seine, France)], aPTT (STA cephascreen STAGO, Diagnostica Stago, Asnieres-sur-Seine, France), PT and INR (STA Neoplastine CI Plus, Diagnostica Stago, Asnieres-sur-Seine, France) were performed with blood samples of approximately 3 ml collected by venipuncture into a tube with citrate (3.2%; Sarsted1, Wedel, Germany). The controls used were STA COAG control N+P, device: STA R evolution and STA Compact for coagulometric mothodology. Platelet count was performed on plasma samples with ethylenediamine tetraacetic acid (EDTA-tube; 3.2%; Sarsted1, Wedel, Germany) with E Check XE control (XE 2100, Sysmex, São Paulo, Brazil).
Coagulopathy was defined according to changes in CCT as follows: thrombocytopenia <150 x10 3 /mm 3 , serum fibrinogen concentration <150 mg/dL or prolonged global coagulation time, such as INR >1.5 and TTPa >32 seconds [18] .
Transfusion therapy. Transfusion practice for management of active bleeding at Hospital Israelita Albert Einstein by using allogenic blood components (FFP, platelets and cryoprecipitate), coagulation factor concentrates (fibrinogen concentrate and PCC) and hemostatic agents were performed according to CCT and physician discretion. FFP (10 mL/kg body weight) or PCC (25 UI/kg body weight) was administered if INR was >1.5. For prolonged aPTT >32 sec, FFP (10 mL/kg body weight) was administered. When serum fibrinogen was <150 mg/dL, either cryoprecipitate (1-2 units/10 kg of body weight) or fibrinogen concentrate (2 to 4g) was administered. Patients with platelet count <50 x10
Statistical analysis
Categorical variables were presented as absolute and relative frequencies. Quantitative variables were presented as average and standard deviation (SD) or median and interquartile range (IQR) when appropriate. The pattern of distribution of continuous variables was evaluated using the Kolmogorov-Smirnov test.
Comparisons between groups of patients with different coagulation profile (normal, hypocoagulability and hypercoagulability) according to ROTEM and CCT were performed. Proportions were compared using chi-square test or Fisher's exact test when assumptions for Chisquare use were violated. Continuous variables were compared using analysis of variance with one factor (ANOVA) followed by Tukey test. In case of non-normal distribution of study variables, Kruskal-Wallis test followed by Mann-Whitney U test were applied. The level of significance was adjusted according to Bonferroni correction after multiple comparisons.
Two-tailed tests were used, and when p value was <0.05, the test was considered statistically significant. SPSS™ (IBM™ Statistical Package for the Social Science version 21.0) was used for statistical analyses.
Results
Patients characteristics
Patients were more frequently male, with a median (IQR) age of 63 (53-74) years and SAPS III score of 47 (35-60) ( Table 1 ). Approximately half of the patients were admitted to ICU due to medical reasons. Sepsis was the most common medical reason for ICU admission while the most common operative admission diagnoses were abdominal and cardiovascular surgery. The overall ICU mortality among studied patients was 24.7% (Table 1) .
Between September 1, 2012 and September 30, 2014, 2811 ROTEM analyses were performed (Fig 1) . After exclusion of 2,280 ROTEM analyses either for belonging to the same patient or for unavailability of concomitant CCT, 531 ROTEM analyses were included in this study (Fig 1) .
Coagulation profile
Results of CCT and ROTEM analyses are shown in Table 2 (Table 3 and S3 Table) . No cases of hyperfibrinolysis were observed in the studied patients.
Association between CCT and Rotem
Results comparing ROTEM parameters with CCT are shown in Table 3 (Table 3 and S3 Table) . Approximately half of hypercoagulable patients according to ROTEM FIBTEM had platelets count <150 x 10 3 /mm 3 (Table 3 and S3 and S4 Tables).
Administered treatment
Based on CCT results, more than one-third of bleeding patients received at least one type of blood component transfusion and approximately 34% of patients received coagulation factor concentrates or hemostatic drugs (Table 4 and S8 Table) . The main blood component used was platelet concentrates (25.8%) followed by FFP (15.6%), while fibrinogen concentrate was the most frequently administered coagulation factor concentrate (Table 4 and S8 Table) . most common administered blood component was platelet concentrate followed by FFP, while fibrinogen concentrate was the most frequently administered coagulation factor concentrate (Table 5) .
Administered treatment and Rotem profile
Discussion
The main finding of our study was that approximately half of bleeding patients with a normocoagulable state by ROTEM showed coagulopathy according to CCT, expressed predominantly by thrombocytopenia and prolongation of aPTT. Moreover, approximately one in five patients received platelet concentrates transfusion based on a low platelet count and more than 10% received FFP based on changes in CCT, yet both groups presented normal thromboelastometry. Opposite to our findings, Halset and cols. demonstrated that more than 70% of adult patients admitted to ICU without bleeding or blood component transfusion in the preceding 24 hours exhibited a hypercoagulable profile on thromboelastography (TEG) [19] . Nevertheless, similarly to our findings, Ostrowski and cols. observed that approximately half of severe sepsis patients admitted to ICU presented normal coagulation, followed by hypocoagulability (30%) and hypercoagulable profile [20] . This disparity may be explained at least in part by different reference values of ROTEM used to define hypo-and hypercoagulability in such studies [21] . Contradictory findings about agreements between CCT and TEG/ROTEM to access the coagulation profile in critically ill patients have been reported [19, 22, 23] . While a poor agreement between CCT and TEG parameters to detect hypocoagulability in patients undergoing elective surgery has been reported by Ågren and cols. [22] , good correlations between TEG and CCT have been described in elderly fractured patients [24] and in severe chronic liver patients [25] .
Coagulopathy, defined by CCT, such as thrombocytopenia, prolongation of coagulation times (PT and aPTT) and reduction and/or dysfunction of plasma fibrinogen is common in critically ill patients [26] . The incidence of platelets <150 x 10 3 /mm 3 and <50 x 10 3 /mm 3 in critically ill patients can vary between 35-44% and 12-15%, respectively [27] . Prolongation of clotting times, PT or aPTT occurs in approximately 14-28% of critically ill patients [27] . The challenge at bedside is to distinguish between patients admitted to ICU presenting laboratory abnormalities without increased bleeding risk and those prone to developing severe bleeding as a result of coagulopathy, either spontaneously or due to surgical/invasive procedures. Conventional coagulation tests only access 5% of thrombin generation process and represent weak predictors of bleeding in critically ill patients [28] . Conventional coagulation tests are performed on plasma samples in the absence of blood cells at a temperature of 37˚C [29] . Moreover, CCT results can take up to 45 minutes to be available at bedside, making a prompt and precise approach of the critically ill patient with massive bleeding impossible [30] .
Thromboelastometry allows an overall assessment of coagulation, including thrombin generation process, fibrin polymerization, clot strength and clot lysis in real time [31] . Furthermore, ROTEM allows early identification of specific coagulation disorders such as hypofibrinogenemia, hyperfibrinolysis and coagulation factors deficiency. Comparison of clot firmness in the EXTEM with clot firmness in FIBTEM allows the platelet component to be assessed [31] . Therefore, it has been demonstrated that thromboelastometry is an effective approach to guide transfusion therapy, according to individual needs [3] . Nevertheless, it is important to emphasize that platelets function in the strictest sense, effects of acetyl salicylic acid and adenosine-diphosphate (ADP) receptor antagonists cannot be determined by the ROTEM [32, 33] . Isolated evaluation of platelet count is unable to predict bleeding risk, since clot strength resulting from the interaction between platelets, plasma fibrinogen and factor XIII is not considered in CCT [33] . Thrombocytopenia may overestimate bleeding risk in critically ill patients, who often present high fibrinogen plasma levels, which is determining for clot firmness [34] . Furthermore, qualitative changes in fibrinogen function is not identified by the quantitative Clauss method, compromising bleeding risk analysis based on plasma fibrinogen levels [35] . Clot strength increases in a fibrinogen concentration-dependent manner, regardless of platelet count [34] . Conventional coagulation tests cannot address the relationship between platelets and fibrinogen. As a result, patients with a low platelet count might be assumed to have an increased risk of bleeding when accessed by CCT [36] . However, ROTEM allows evaluation of interaction between fibrinogen and platelets (maximum clot firmness), functionally (qualitatively) and quantitatively [32] .
Many patients will exhibited a normocoagulable profile according to ROTEM, despite a low platelet count, possibly due to higher fibrinogen production secondary to an acute phase disease [37] . Even though the critically ill patient will develop thrombocytopenia usually on the 4 th day of hospitalization [38] for many different reasons (sepsis, heparin, drugs, and surgery), not necessarily all those patients will present a higher risk of bleeding and the need for platelet concentrates transfusion [18] . These patients often produce a higher amount of fibrinogen from the liver, compensating platelet deficiency and preserving clot strength [39, 40] . Thus, the practice of guiding blood components transfusion based only on changes in CCT may increase exposure of critically ill patients to different adverse events, with a negative impact on outcomes [12] . Our study has some limitations. First, this study was observational, retrospective, and singlecenter, which may compromise the external validity of our findings. Nevertheless, unlike other studies, our study involved a larger sample of critically ill patients with different medical or surgical diagnoses. Second, the use of anticoagulants and antiplatelet drugs were not available or recorded;thus our findings should be interpreted with caution. Due to the observational nature of this study, we could not determine if allogenic blood components, coagulation factor concentrates and hemostatic agents have been administered according to our hospital guidelines.
Conclusion
Most of the critically ill patients admitted to ICU exhibited a normal coagulation profile according to ROTEM, although CCT suggested presence of coagulopathy. Transfusion therapy based on CCT led to a large number of patients receiving allogeneic blood transfusion, possibly unnecessarily. The use of ROTEM to identify the underlying coagulopathy and as a transfusion guide in this population of critically ill patients has the potential to avoid inappropriate allogeneic blood product transfusions. 
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